• Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder

    Zimmerman AW, Singh K, Connors SL, Liu H, Panjwani AA, Lee LC, Diggins E, Foley A, Melnyk S, Singh IN, James SJ, Frye RE, Fahey JW. Randomized controlled trial of sulforaphane and metabolite discovery in children with Autism Spectrum Disorder. Mol Autism. 2021 May 25;12(1):38. doi: 10.1186/s13229-021-00447-5. Erratum in: Mol Autism. 2021 Jun 16;12(1):44. PMID: 34034808; PMCID: PMC8146218.

  • Emerging biomarkers in autism spectrum disorder: a systematic review

    Frye RE, Vassall S, Kaur G, Lewis C, Karim M, Rossignol D. Emerging biomarkers in autism spectrum disorder: a systematic review. Ann Transl Med. 2019 Dec;7(23):792. doi: 10.21037/atm.2019.11.53. PMID: 32042808; PMCID: PMC6989979.

  • Mitochondrial Fatty Acid β-Oxidation and Resveratrol Effect in Fibroblasts from Patients with Autism Spectrum Disorder

    Barone R, Bastin J, Djouadi F, Singh I, Karim MA, Ammanamanchi A, McCarty PJ, Delhey L, Shannon R, Casabona A, Rizzo R, Frye RE. Mitochondrial Fatty Acid β-Oxidation and Resveratrol Effect in Fibroblasts from Patients with Autism Spectrum Disorder. J Pers Med. 2021 Jun 4;11(6):510. doi: 10.3390/jpm11060510. PMID: 34199819; PMCID: PMC8229571.

  • Physiological mediators of prenatal environmental influences in autism spectrum disorder

    Frye RE, Cakir J, Rose S, Palmer RF, Austin C, Curtin P. Physiological mediators of prenatal environmental influences in autism spectrum disorder. Bioessays. 2021 Sep;43(9):e2000307. doi: 10.1002/bies.202000307. Epub 2021 Jul 14. PMID: 34260745.

  • A Systematic Review and Meta-Analysis of Immunoglobulin G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism Spectrum Disorder

    Rossignol DA, Frye RE. A Systematic Review and Meta-Analysis of Immunoglobulin G Abnormalities and the Therapeutic Use of Intravenous Immunoglobulins (IVIG) in Autism Spectrum Disorder. J Pers Med. 2021 May 30;11(6):488. doi: 10.3390/jpm11060488. PMID: 34070826; PMCID: PMC8229039.

  • Locked-in Intact Functional Networks in Children with Autism Spectrum Disorder: A Case-Control Study

    Pines AR, Sussman B, Wyckoff SN, McCarty PJ, Bunch R, Frye RE, Boerwinkle VL. Locked-in Intact Functional Networks in Children with Autism Spectrum Disorder: A Case-Control Study. J Pers Med. 2021 Aug 28;11(9):854. doi: 10.3390/jpm11090854. PMID: 34575631; PMCID: PMC8465896.

  • MicroRNA Expression Profiles in Autism Spectrum Disorder: Role for miR-181 in Immunomodulation

    Frye RE, Rose S, McCullough S, Bennuri SC, Porter-Gill PA, Dweep H, Gill PS. MicroRNA Expression Profiles in Autism Spectrum Disorder: Role for miR-181 in Immunomodulation. J Pers Med. 2021 Sep 17;11(9):922. doi: 10.3390/jpm11090922. PMID: 34575699; PMCID: PMC8469245.

  • The Effectiveness of Cobalamin (B12) Treatment for Autism Spectrum Disorder: A Systematic Review and Meta-Analysis

    Rossignol DA, Frye RE. The Effectiveness of Cobalamin (B12) Treatment for Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. J Pers Med. 2021 Aug 11;11(8):784. doi: 10.3390/jpm11080784. PMID: 34442428; PMCID: PMC8400809.

taca logo

TACA provides education, support, and hope to families living with autism. Thank you for your support.

maps logo

Today’s complex disorders (Autism, Lyme, PANS, COVID etc) require a new understanding of the role inflammation, toxins, mitochondrial dysfunction etc are playing. Today’s patients need physicians to obtain new strategies, new diagnostic tools, & new perspectives. MAPS delivers these from leading clinicians & researchers. MAPS takes today’s complex health issues & provides a comprehensive path for clinicians to follow for successful outcomes. MAPS teaches tomorrow’s medicine today. Be part of the future – attend MAPS!